Cowen and Company reiterated their buy rating on shares of Juno Therapeutics, Inc. (NASDAQ:JUNO) in a research report sent to investors on Friday morning.

JUNO has been the topic of several other research reports. Morgan Stanley restated an equal weight rating and set a $43.00 target price (up previously from $27.00) on shares of Juno Therapeutics in a research note on Friday, October 6th. Vetr upgraded shares of Juno Therapeutics from a strong sell rating to a sell rating and set a $25.50 target price on the stock in a research note on Monday, August 14th. Zacks Investment Research cut shares of Juno Therapeutics from a hold rating to a sell rating in a research note on Monday, August 28th. Raymond James Financial, Inc. upgraded shares of Juno Therapeutics from a market perform rating to an outperform rating and set a $45.00 target price on the stock in a research note on Tuesday, August 29th. Finally, Wedbush restated an outperform rating and set a $64.00 target price (up previously from $42.00) on shares of Juno Therapeutics in a research note on Thursday. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have assigned a buy rating to the stock. The company presently has a consensus rating of Hold and an average target price of $44.20.

Juno Therapeutics (NASDAQ:JUNO) traded down $1.71 on Friday, reaching $56.77. 1,316,180 shares of the company’s stock traded hands, compared to its average volume of 2,170,000. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics has a 1-year low of $17.52 and a 1-year high of $61.59.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. The business had revenue of $44.80 million for the quarter, compared to analysts’ expectations of $18.12 million. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business’s revenue for the quarter was up 115.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.57) EPS. analysts expect that Juno Therapeutics will post -3.62 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.watchlistnews.com/cowen-and-company-reaffirms-buy-rating-for-juno-therapeutics-inc-juno/1683314.html.

In related news, EVP Robert Azelby sold 6,666 shares of the stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $54.95, for a total value of $366,296.70. Following the completion of the sale, the executive vice president now directly owns 79,998 shares of the company’s stock, valued at approximately $4,395,890.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard Klausner sold 12,000 shares of the stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $42.66, for a total transaction of $511,920.00. Following the completion of the sale, the director now directly owns 783,536 shares of the company’s stock, valued at $33,425,645.76. The disclosure for this sale can be found here. Insiders sold a total of 79,670 shares of company stock valued at $3,553,777 over the last three months. 15.26% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in JUNO. BlackRock Inc. increased its holdings in Juno Therapeutics by 31,399.7% in the 1st quarter. BlackRock Inc. now owns 4,183,793 shares of the biopharmaceutical company’s stock worth $92,838,000 after acquiring an additional 4,170,511 shares in the last quarter. Redmile Group LLC purchased a new stake in Juno Therapeutics in the 2nd quarter worth approximately $66,344,000. Jennison Associates LLC increased its holdings in Juno Therapeutics by 162.0% in the 3rd quarter. Jennison Associates LLC now owns 1,988,708 shares of the biopharmaceutical company’s stock worth $89,213,000 after acquiring an additional 1,229,622 shares in the last quarter. Wasatch Advisors Inc. purchased a new stake in Juno Therapeutics in the 2nd quarter worth approximately $19,787,000. Finally, Marshall Wace North America L.P. purchased a new stake in Juno Therapeutics in the 2nd quarter worth approximately $9,693,000. 67.12% of the stock is owned by institutional investors.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.